Gene: AKAP9

10142
AKAP-9|AKAP350|AKAP450|CG-NAP|HYPERION|LQT11|MU-RMS-40.16A|PPP1R45|PRKA9|YOTIAO
A-kinase anchoring protein 9
protein-coding
7q21.2
Ensembl:ENSG00000127914 MIM:604001 Vega:OTTHUMG00000131127 UniprotKB:Q99996
NG_011623.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.000e+0 (AD)  3.063e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12536529chr7:92054772 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RALGAPA10.933
MYO9A0.931
HECTD10.927
ARFGEF10.926
TRAPPC80.925
RALGAPB0.918
BOD1L10.917
KIAA11090.914
BDP10.911
ATG2B0.909

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.482
OR4F29-0.443
CSAG1-0.367
HMX1-0.328
MTRNR2L6-0.322
PGF-0.321
S100A1-0.32
S100A14-0.316
RAB13-0.313
NKX6-1-0.31

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0252051,10-phenanthroline"1,10-phenanthroline results in increased expression of AKAP9 mRNA"19502547
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of AKAP9 mRNA"20453058
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA"25510870
C0297902,2',3',4,4',5-hexachlorobiphenyl"2,2',3',4,4',5-hexachlorobiphenyl results in increased expression of AKAP9 mRNA"23829299
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"2,5,2',5'-tetrachlorobiphenyl results in decreased expression of AKAP9 mRNA"23829299
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of AKAP9 mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA"27188386
C0021664-methyl-7-diethylaminocoumarin4-methyl-7-diethylaminocoumarin results in increased expression of AKAP9 mRNA19502547
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of AKAP9 mRNA21420995
D000082AcetaminophenAcetaminophen affects the expression of AKAP9 mRNA17562736
D000086AcetazolamideAcetazolamide results in increased expression of AKAP9 mRNA19274763
D020106AcrylamideAcrylamide results in decreased expression of AKAP9 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of AKAP9 mRNA19770486
D000393Air PollutantsAir Pollutants analog results in decreased expression of AKAP9 mRNA21757418
D000643Ammonium ChlorideAmmonium Chloride affects the expression of AKAP9 mRNA16483693
D018501Antirheumatic Agents[Antirheumatic Agents co-treated with Methotrexate] results in decreased expression of AKAP9 mRNA16817978
D001151ArsenicArsenic results in decreased expression of AKAP9 mRNA16835338
C006632arsenic trioxidearsenic trioxide affects the expression of AKAP9 protein15894607
C006632arsenic trioxidearsenic trioxide results in increased expression of AKAP9 mRNA20458559
C006632arsenic trioxide[Tretinoin co-treated with arsenic trioxide] results in decreased expression of AKAP9 protein15894607
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of AKAP9 mRNA20713471
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of AKAP9 mRNA"26238291
D004958EstradiolEstradiol results in decreased expression of AKAP9 mRNA20068009
C006780bisphenol Abisphenol A affects the expression of AKAP9 mRNA25181051
C006780bisphenol Abisphenol A results in decreased expression of AKAP9 protein24552547
C006780bisphenol Abisphenol A results in decreased expression of AKAP9 mRNA26794494
C013418bromfenacoumbromfenacoum results in increased expression of AKAP9 protein28903499
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA22079614
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of AKAP9 mRNA15336504
C018475butyraldehydebutyraldehyde results in decreased expression of AKAP9 mRNA26079696
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of AKAP9 mRNA24982889
C055494caffeic acid phenethyl ester[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AKAP9 mRNA20360939
C084597chlorcyclizinechlorcyclizine results in decreased expression of AKAP9 mRNA21058326
D002737ChloropreneChloroprene results in increased expression of AKAP9 mRNA23125180
D004390Chlorpyrifos[Copper co-treated with Chlorpyrifos] results in decreased expression of AKAP9 mRNA21356183
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of AKAP9 mRNA28472532
D007464Clioquinol[Clioquinol binds to Copper] which results in decreased expression of AKAP9 protein18346929
D003010ClorgylineClorgyline results in increased expression of AKAP9 mRNA19691856
C018021cobaltous chloridecobaltous chloride results in increased expression of AKAP9 mRNA19376846
D003300Copper[Clioquinol binds to Copper] which results in decreased expression of AKAP9 protein18346929
D003300Copper[Copper co-treated with Chlorpyrifos] results in decreased expression of AKAP9 mRNA21356183
D003300CopperCopper results in decreased expression of AKAP9 mRNA21356183
D019327Copper SulfateCopper Sulfate results in decreased expression of AKAP9 mRNA19549813
D016572CyclosporineCyclosporine affects the expression of AKAP9 mRNA25562108
C093628cyproconazolecyproconazole results in decreased expression of AKAP9 mRNA22334560
D003703DemecolcineDemecolcine results in increased expression of AKAP9 mRNA23649840
C000944dicrotophosdicrotophos results in decreased expression of AKAP9 mRNA28302478
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AKAP9 mRNA20360939
D004052DiethylnitrosamineDiethylnitrosamine results in increased expression of AKAP9 mRNA19041683
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of AKAP9 mRNA21658437
D004237DiuronDiuron results in decreased expression of AKAP9 mRNA25152437
D004640EmetineEmetine inhibits the reaction [sodium arsenite affects the localization of AKAP9 protein]19073175
C109476epoxiconazoleepoxiconazole results in decreased expression of AKAP9 mRNA22334560
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of AKAP9 mRNA23649840
D018120FinasterideFinasteride results in increased expression of AKAP9 mRNA24136188
D005557FormaldehydeFormaldehyde results in decreased expression of AKAP9 mRNA20655997
D005557FormaldehydeFormaldehyde results in increased expression of AKAP9 mRNA23649840
C544151jinfukangjinfukang results in decreased expression of AKAP9 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of AKAP9 mRNA24796395
C410337K 7174K 7174 results in increased expression of AKAP9 mRNA24086573
D007649KetamineKetamine results in decreased expression of AKAP9 mRNA20080153
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of AKAP9 mRNA"24972896
D058185Magnetite Nanoparticles[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of AKAP9 mRNA21641980
D008727Methotrexate[Antirheumatic Agents co-treated with Methotrexate] results in decreased expression of AKAP9 mRNA16817978
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of AKAP9 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of AKAP9 mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of AKAP9 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of AKAP9 mRNA"25554681
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of AKAP9 mRNA19812364
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of AKAP9 mRNA25729387
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of AKAP9 mRNA"25510870
C410127PCB 180PCB 180 results in decreased expression of AKAP9 mRNA23829299
D010416PentachlorophenolPentachlorophenol results in increased expression of AKAP9 mRNA23892564
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of AKAP9 mRNA27153767
D010634PhenobarbitalPhenobarbital results in decreased expression of AKAP9 mRNA23091169
D010795Phthalic AcidsPhthalic Acids results in increased expression of AKAP9 mRNA21061450
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of AKAP9 mRNA19710929
D010936Plant ExtractsPlant Extracts results in increased expression of AKAP9 mRNA23557933
D011374ProgesteroneProgesterone results in increased expression of AKAP9 mRNA23012394
D011374ProgesteroneProgesterone results in decreased expression of AKAP9 mRNA18070364
C045950propiconazolepropiconazole results in decreased expression of AKAP9 mRNA21278054|2233456
C059514resveratrolresveratrol results in increased expression of AKAP9 mRNA19228061
D012402RotenoneRotenone results in decreased expression of AKAP9 mRNA19013527
D012524SarinSarin results in decreased expression of AKAP9 mRNA19522546
D012524SarinSarin results in increased expression of AKAP9 mRNA19522546
D012715Sesame OilSesame Oil results in increased expression of AKAP9 mRNA29191790
C017947sodium arseniteEmetine inhibits the reaction [sodium arsenite affects the localization of AKAP9 protein]19073175
C017947sodium arsenitesodium arsenite affects the localization of AKAP9 protein19073175
C017947sodium arsenitesodium arsenite affects the methylation of AKAP9 gene28589171
C017947sodium arsenitesodium arsenite results in decreased expression of AKAP9 mRNA28595984
D004113Succimer[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of AKAP9 mRNA21641980
D013467SulindacSulindac results in decreased expression of AKAP9 mRNA24136188
C061133tamibarotenetamibarotene results in decreased expression of AKAP9 mRNA15498508
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of AKAP9 mRNA21570461|2468072
D013750TetrachloroethyleneTetrachloroethylene results in increased expression of AKAP9 mRNA28973375
D013849ThimerosalThimerosal results in increased expression of AKAP9 mRNA27188386
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of AKAP9 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of AKAP9 mRNA25729387
D014212Tretinoin[Tretinoin co-treated with arsenic trioxide] results in decreased expression of AKAP9 protein15894607
D014212TretinoinTretinoin results in decreased expression of AKAP9 mRNA15498508
D014212TretinoinTretinoin results in increased expression of AKAP9 protein15894607
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of AKAP9 mRNA24935251|2627250
D014302Trinitrobenzenesulfonic AcidTrinitrobenzenesulfonic Acid results in increased expression of AKAP9 mRNA17982090
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP9 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of AKAP9 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of AKAP9 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in decreased methylation of AKAP9 gene29154799
D024483Vitamin K 3Vitamin K 3 affects the expression of AKAP9 mRNA20044591

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003677DNA binding-IEA-  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005102signaling receptor binding-TAS9482789  
GO:0005515protein binding-IPI12163479  16980960  19242490  20466722  23455924  27666745  
28089391  29162697  
GO:0015459potassium channel regulator activity-IBA21873635  
GO:0015459potassium channel regulator activity-IMP16002409  
GO:0032947protein-containing complex scaffold activity-IBA21873635  
GO:0032947protein-containing complex scaffold activity-IDA11799244  27666745  
GO:0034237protein kinase A regulatory subunit binding-IBA21873635  
GO:0034237protein kinase A regulatory subunit binding-IPI17911601  
GO:0044325ion channel binding-IPI11799244  16002409  18093912  
GO ID GO Term Qualifier Evidence PubMed
GO:0000086G2/M transition of mitotic cell cycle-TAS-  
GO:0000165MAPK cascade-TAS-  
GO:0007020microtubule nucleation-IMP19242490  
GO:0007165signal transduction-TAS10390370  
GO:0007194negative regulation of adenylate cyclase activity-IEA-  
GO:0007268chemical synaptic transmission-TAS9482789  
GO:0010389regulation of G2/M transition of mitotic cell cycle-TAS-  
GO:0031116positive regulation of microtubule polymerization-IMP29162697  
GO:0033138positive regulation of peptidyl-serine phosphorylation-IBA21873635  
GO:0033138positive regulation of peptidyl-serine phosphorylation-IMP18093912  
GO:0051602response to electrical stimulus-IEA-  
GO:0051661maintenance of centrosome location-IBA21873635  
GO:0051661maintenance of centrosome location-IMP25657325  
GO:0060306regulation of membrane repolarization-IMP16002409  
GO:0060307regulation of ventricular cardiac muscle cell membrane repolarization-IBA21873635  
GO:0060307regulation of ventricular cardiac muscle cell membrane repolarization-IMP18093912  
GO:0071320cellular response to cAMP-IMP16002409  18093912  
GO:0086091regulation of heart rate by cardiac conduction-IMP18093912  
GO:0097711ciliary basal body-plasma membrane docking-TAS-  
GO:0098909regulation of cardiac muscle cell action potential involved in regulation of contraction-IMP18093912  
GO:1901018positive regulation of potassium ion transmembrane transporter activity-IBA21873635  
GO:1901018positive regulation of potassium ion transmembrane transporter activity-IMP16002409  
GO:1903358regulation of Golgi organization-IBA21873635  
GO:1903358regulation of Golgi organization-IDA27666745  
GO ID GO Term Qualifier Evidence PubMed
GO:0005794Golgi apparatus-IBA21873635  
GO:0005794Golgi apparatus-IDA12163479  27666745  
GO:0005795Golgi stack-IBA21873635  
GO:0005795Golgi stack-IDA19242490  
GO:0005801cis-Golgi network-IBA21873635  
GO:0005801cis-Golgi network-IDA24648492  
GO:0005813centrosome-IBA21873635  
GO:0005813centrosome-IDA20096683  21399614  24648492  25657325  29162697  
GO:0005829cytosol-TAS-  
GO:0005856cytoskeleton-TAS9482789  
GO:0008076voltage-gated potassium channel complex-IDA11799244  
GO:0043025neuronal cell body-IEA-  
GO:0043231intracellular membrane-bounded organelle-IDA-  
GO:0044307dendritic branch-IEA-  
GO:0097060synaptic membrane-IBA21873635  
GO:0097060synaptic membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmissionTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-162582Signal TransductionTAS
R-HSA-1640170Cell CycleTAS
R-HSA-1643685DiseaseTAS
R-HSA-1852241Organelle biogenesis and maintenanceTAS
R-HSA-2565942Regulation of PLK1 Activity at G2/M TransitionTAS
R-HSA-380259Loss of Nlp from mitotic centrosomesTAS
R-HSA-380270Recruitment of mitotic centrosome proteins and complexesTAS
R-HSA-380284Loss of proteins required for interphase microtubule organization from the centrosomeTAS
R-HSA-380287Centrosome maturationTAS
R-HSA-380320Recruitment of NuMA to mitotic centrosomesTAS
R-HSA-397014Muscle contractionTAS
R-HSA-438064Post NMDA receptor activation eventsTAS
R-HSA-438066Unblocking of NMDA receptor, glutamate binding and activationTAS
R-HSA-442729CREB phosphorylation through the activation of CaMKIITAS
R-HSA-442742CREB phosphorylation through the activation of RasTAS
R-HSA-442755Activation of NMDA receptor and postsynaptic eventsTAS
R-HSA-442982Ras activation upon Ca2+ influx through NMDA receptorTAS
R-HSA-453274Mitotic G2-G2/M phasesTAS
R-HSA-5576890Phase 3 - rapid repolarisationTAS
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576893Phase 2 - plateau phaseTAS
R-HSA-5617833Cilium AssemblyTAS
R-HSA-5620912Anchoring of the basal body to the plasma membraneTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6802952Signaling by BRAF and RAF fusionsTAS
R-HSA-6802957Oncogenic MAPK signalingTAS
R-HSA-68877Mitotic PrometaphaseTAS
R-HSA-68886M PhaseTAS
R-HSA-69275G2/M TransitionTAS
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-8854518AURKA Activation by TPX2TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21314694Genomewide association analysis of symptoms of alcohol dependence in the molecular genetics of schizophrenia (MGS2) control sample. (2011 May)Kendler KSAlcohol Clin Exp Res
20106900International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. (2010 Apr)Truong TCarcinogenesis
24452374A-kinase anchoring proteins contribute to loss of E-cadherin and bronchial epithelial barrier by cigarette smoke. (2014 Mar 15)Oldenburger AAm J Physiol Cell Physiol